Biocon has entered into a global partnership with Sandoz, a division of Swiss pharmaceutical Novartis.

As per the terms of agreement, both companies will develop, manufacture and commercialize multiple biosimilars in immunology and oncology. They will also share responsibility for end-to-end development, manufacturing and global regulatory approvals for various products and will have a cost and profit share arrangement globally.

Moreover, Sandoz will head commercialization in North America and the European Union, while Biocon will head commercialization in the rest of the world.

Read EquityPandit’s Technical Analysis of  Nifty Pharma